Focused ultrasound-enhanced carboplatin delivery improves radiotherapy response and survival in a preclinical glioblastoma model

Rationale Glioblastoma is highly resistant to conventional therapies due to the limited penetration of chemotherapeutics across the blood-brain and blood-tumor barriers (BBB, BTB). Although platinum-based drugs show strong cytotoxic and radiosensitizing properties in several cancers, their inability to achieve therapeutic concentrations within the central nervous system (CNS) severely limits their efficacy in brain tumors. This study investigated whether focused ultrasound (FUS)-mediated BBB/BTB disruption combined with intravenous carboplatin and stereotactic radiotherapy could improve drug delivery, tumor control, and survival in a preclinical glioblastoma model. Methods F98 glioma-bearing rats were treated with a single dose of 15 Gy radiation therapy (RT), carboplatin only, carboplatin + RT, FUS + carboplatin or FUS + carboplatin + RT. FUS-mediated permeabilization was confirmed by magnetic resonance imaging (MRI), and platinum accumulation was quantified by inductively coupled plasma mass spectrometry and synchrotron X-ray fluorescence. Tumor progression and microenvironmental changes were monitored using multiparametric MRI (diffusion, perfusion, and vascular permeability), followed by voxel-wise clustering analysis and histopathological validation. Results The FUS + carboplatin + RT group demonstrated the strongest therapeutic benefit, compared to all other treatment groups, yielding up to a 122% increase in median survival relative to the untreated group. This treatment also reduced necrotic core expansion and induced a transient increase in tumor perfusion, suggesting improved vascular function. FUS enhanced carboplatin delivery to both the tumor and peritumoral brain, with platinum distribution closely correlating with MRI signal enhancement. Voxel-wise clustering of multiparametric MRI identified biologically distinct tumor regions that were subsequently validated by immunohistochemistry. Conclusion The combination of FUS-mediated carboplatin delivery and radiotherapy represents a safe, non-invasive strategy that enhances drug delivery and improves survival in an aggressive preclinical model of glioblastoma. By overcoming a major limitation of current therapies, this approach shows promising potential for clinical translation. Keywords Glioblastoma, Focused Ultrasound, Blood-Brain Barrier, Chemotherapy, Radiotherapy

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-17
DOI
https://doi.org/10.64898/2026.11.17.766937
Primary Topic
Ultrasound and Hyperthermia Applications
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Focused ultrasound-enhanced carboplatin delivery improves radiotherapy response and survival in a preclinical glioblastoma model

Anne‐Laure Bulin, Erik Dumont, Benoît Chovelon, Sarvenaz Keshmiri et al.
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Ultrasound and Hyperthermia Applications
preprint

Focused ultrasound-enhanced carboplatin delivery improves radiotherapy response and survival in a preclinical glioblastoma model

Anne‐Laure Bulin, Erik Dumont, Benoît Chovelon, Sarvenaz Keshmiri, Vasile Stupar, Anthony Delalande, Alexandre Leboucher, Benjamin Lemasson, Sébastien Rigollet, Thomas Ador, Emmanuel Barbier, Jean-François Adam, Marie D’Allemagne, Jean‐Luc Ravanat, Sarra Dbira, Helene Elleaume
preprint en

Abstract

Rationale Glioblastoma is highly resistant to conventional therapies due to the limited penetration of chemotherapeutics across the blood-brain and blood-tumor barriers (BBB, BTB). Although platinum-based drugs show strong cytotoxic and radiosensitizing properties in several cancers, their inability to achieve therapeutic concentrations within the central nervous system (CNS) severely limits their efficacy in brain tumors. This study investigated whether focused ultrasound (FUS)-mediated BBB/BTB disruption combined with intravenous carboplatin and stereotactic radiotherapy could improve drug delivery, tumor control, and survival in a preclinical glioblastoma model. Methods F98 glioma-bearing rats were treated with a single dose of 15 Gy radiation therapy (RT), carboplatin only, carboplatin + RT, FUS + carboplatin or FUS + carboplatin + RT. FUS-mediated permeabilization was confirmed by magnetic resonance imaging (MRI), and platinum accumulation was quantified by inductively coupled plasma mass spectrometry and synchrotron X-ray fluorescence. Tumor progression and microenvironmental changes were monitored using multiparametric MRI (diffusion, perfusion, and vascular permeability), followed by voxel-wise clustering analysis and histopathological validation. Results The FUS + carboplatin + RT group demonstrated the strongest therapeutic benefit, compared to all other treatment groups, yielding up to a 122% increase in median survival relative to the untreated group. This treatment also reduced necrotic core expansion and induced a transient increase in tumor perfusion, suggesting improved vascular function. FUS enhanced carboplatin delivery to both the tumor and peritumoral brain, with platinum distribution closely correlating with MRI signal enhancement. Voxel-wise clustering of multiparametric MRI identified biologically distinct tumor regions that were subsequently validated by immunohistochemistry. Conclusion The combination of FUS-mediated carboplatin delivery and radiotherapy represents a safe, non-invasive strategy that enhances drug delivery and improves survival in an aggressive preclinical model of glioblastoma. By overcoming a major limitation of current therapies, this approach shows promising potential for clinical translation. Keywords Glioblastoma, Focused Ultrasound, Blood-Brain Barrier, Chemotherapy, Radiotherapy

bioRxiv (Cold Spring Harbor Laboratory)
Institut polytechnique de Grenoble (FR), Université d'Orléans (FR), Centre National de la Recherche Scientifique (FR), Inserm (FR), Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR), Centre Hospitalier Universitaire de Grenoble (FR), European Synchrotron Radiation Facility (FR), Grenoble Institute of Neurosciences (FR), Institut pour l'avancée des biosciences (FR), Guided Therapeutics (United States) (US), Systèmes Moléculaires et nanoMatériaux pour l'Énergie et la Santé (FR), Synchrotron Radiation for Biomedicine (FR), Laboratoire Interdisciplinaire pour l’Innovation et la Recherche en Santé d’Orléans (FR), IRMaGe (FR), Université Grenoble Alpes (FR)
Ligue Contre le Cancer
Good health and well-being
Ultrasound and Hyperthermia Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon